Two US Food and Drug Administration (FDA)approved CAR-T cell products targeting B cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma, Idecabtagene vicleucel (Ide-cel, bb2121, Celgene/BMS) and Ciltacabtagene autoleucel (Ciltacel, JNJ-68284528/LCAR-B38M, Janssen), have provided a new strategy to some extent. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.